Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Mise à jour : Il y a 4 ans
Référence : NCT02824575

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.


Critère d'inclusion

  • Breast Cancer,Breast Adenocarcinoma,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Recurrent Breast Carcinoma,Stage IV Breast Cancer

Liens